Topical pain management with the 5% lidocaine medicated plaster – a review

Abstract

Background:

The topical 5% lidocaine medicated plaster is recommended as first-line treatment for localized peripheral neuropathic pain.

Scope:

In order to provide an overview of the efficacy and safety of the lidocaine plaster in the treatment of different neuropathic pain conditions, all efficacy and safety studies (randomized, controlled, or open-label with well described methodology), case reports, and pharmacological studies on the lidocaine plaster retrieved from a PubMed literature research (1960 – March 2012) plus additional references identified from retrieved articles were included.

Findings:

The lidocaine plaster is efficacious in the treatment of neuropathic pain symptoms associated with previous herpes zoster infection. Results from a large open-label controlled study suggest that the lidocaine plaster could be at least as effective as systemic pregabalin in the treatment of postherpetic neuralgia and painful diabetic polyneuropathy. Open-label studies indicate efficacy in the treatment of other localized neuropathic pain conditions, such as painful idiopathic sensory polyneuropathy, complex regional pain syndrome, carpal tunnel syndrome sequelae, postsurgical and posttraumatic pain. Quality of life markedly improved in a variety of neuropathic pain conditions and long-term treatment provided sustained relief in patients with neuropathic pain who are responsive to lidocaine plaster. The lidocaine plaster is usually well tolerated. The risk of systemic adverse events and pharmacokinetic interactions with concomitant medication is minimal owing to low systemic exposure.

Conclusions:

Treatment of several, primarily neuropathic and mixed-pain conditions with the 5% lidocaine medicated plaster was found efficacious and safe. Further controlled studies, in particular where only small open-label studies or case reports are available, should be considered.

Keywords::

• 5% lidocaine medicated plaster
• Chronic pain
• Neuropathic pain
• Pain management
• Topical pain treatment

Acknowledgment

The authors wish to thank Elke Grosselindemann (Brett Medical Writing, Australia) and Birgit Brett (Brett Medical Writing, Germany) for writing and editorial assistance and publication coordination.

Notes

*Versatis; also registered as Lidoderm in the USA and Neurodol Tissugel in Switzerland. Versatis is a registered trade name of Grünenthal GmbH, Aachen, Germany. Lidoderm is a registered trade name of Endo Pharmaceuticals, Chadds Ford, PA, USA. Neurodol Tissugel is a registered trade name of IBSA Institut Biochimique SA, Lugano, Switzerland.